Core Viewpoint - NKGen Biotech, Inc. is advancing its innovative NK cell therapeutics, particularly focusing on the presentation of preliminary results for its troculeucel therapy in treating moderate Alzheimer's disease at the upcoming AD/PD™ 2025 conference [1][3]. Company Overview - NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, specializing in the development and commercialization of autologous and allogeneic NK cell therapeutics [6]. - The company is developing troculeucel, a novel patient-specific NK cell immunotherapeutic drug candidate, for neurodegenerative disorders and various cancers [5]. Conference Participation - Paul Y. Song, M.D., the CEO of NKGen, will present at the AD/PD™ 2025 conference, which is a significant event for discussing advancements in Alzheimer's and Parkinson's research [1][2]. - The conference is expected to attract over 4,700 participants from more than 70 countries, showcasing 2,250 abstracts in 2024 [2]. Presentation Details - The presentation titled "Preliminary Cognitive Improvement in Phase 1 Cohort of Moderate Alzheimer's Disease Subjects Treated with Autologous Natural Killer Cells (Troculeucel; SNK01)" will take place on April 5, 2025, focusing on three-month cognitive and biomarker results from the Phase 1 cohort of the clinical trial [3]. - New data from the six-month analysis of this cohort will also be discussed during the presentation [3]. Product Information - Troculeucel, also known as SNK01, has received the International Nonproprietary Name (INN) approval from the World Health Organization (WHO), marking a significant milestone for NKGen in bringing this therapy to market [5].

Core Insights - Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on innovative therapies for cancer and viral infections [1][3] - The company's chief medical officer, Dr. Roger Waltzman, will moderate a panel at the CMO360 Summit on April 7-8, 2025, discussing clinical trial management [1][2] - Indaptus' approach involves a multi-targeted package of immune system-activating signals delivered intravenously, aiming to enhance both innate and adaptive immune responses [3] Company Overview - Indaptus Therapeutics has developed a patented technology utilizing non-pathogenic Gram-negative bacteria to activate immune responses through various receptors [3] - The Decoy product candidates have shown promise in pre-clinical studies, demonstrating activity against various cancers and chronic viral infections such as hepatitis B and HIV [3] - The company emphasizes the potential for reduced intravenous toxicity while maintaining effective immune activation [3] Industry Context - The CMO360 Summit is recognized as a significant event for biotech Chief Medical Officers, facilitating networking and skill development within the industry [2] - The conference aims to advance efficient medicine development and delivery, highlighting the importance of patient diversity and access in the biotech sector [2]

SAN JOSE, Calif., March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II ( ...

Core Insights - Kraig Biocraft Laboratories, Inc. has achieved a significant scientific milestone by engineering the largest known spider silk gene insert into silkworms, nearly doubling the previous record, which enhances the potential for next-generation spider silk fibers with improved strength and flexibility [1][3][4] Group 1: Scientific Achievement - The project was led by Dr. Xiaoli Zhang, the Company's research manager, who is pushing the boundaries of genetic engineering for spider silk production [2] - The breakthrough allows for the creation of larger, more complex proteins with unique mechanical properties, which can be incorporated into silk fibers, expanding the possibilities for spider silk technology [3][4] Group 2: Commercialization Efforts - Kraig Labs is committed to commercializing its current recombinant spider silk production strains while accelerating the development of advanced materials for various applications, including performance textiles, defense, and industrial sectors [4][5] - The Company is rapidly advancing the scale-up of its existing technologies to bring spider silk fibers to market [4][6] Group 3: Future Vision - The CEO, Kim Thompson, emphasized the dual mission of commercializing existing technology while continuously innovating for future advancements in biomaterials [5] - Kraig Labs is investing in the future of spider silk technology and will continue to provide updates on its commercialization efforts and groundbreaking research [6]

Tivic Health Systems, Inc. (NASDAQ:TIVC) Q4 2024 Results Conference Call March 21, 2025 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Lisa Wolf - Interim Chief Financial Officer Operator Welcome to Tivic Health Systems year-end 2024 financial results and operational update conference call. This call has been prerecorded, and the questions you have submitted in advance will be answered following the prior remarks. This call is being webcast and the replay will be available on the I ...

Group 1 - Zai Lab Limited (NASDAQ: ZLAB) has seen its share price increase by over 105% on a 12-month basis and nearly 50% year-to-date [2] - The company markets and sells seven drugs developed by US and European pharmaceutical companies [2] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] Group 2 - Edmund Ingham, a biotech consultant with over 5 years of experience, has created detailed reports on more than 1,000 companies in the biotech, healthcare, and pharma sectors [2]

Core Viewpoint - Silexion Therapeutics is set to present an expanded development plan for its siRNA candidate SIL204 at the upcoming NeauxCancer Conference, following promising preclinical data related to KRAS-driven cancers [1][2][4]. Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for solid tumors driven by KRAS mutations, which are prevalent in human cancers [5]. - The company's first-generation product, LODER™, has shown promising results in a Phase 2 clinical trial for non-resectable pancreatic cancer [5]. - Silexion is advancing its next-generation siRNA candidate, SIL204, which targets a broader range of KRAS mutations and has demonstrated significant potential in preclinical studies [5]. Development Plan - The newly completed strategic plan aims to maximize SIL204's potential through various delivery approaches to tackle the challenges posed by KRAS-driven cancers [2]. - Further details regarding the expanded development plan will be disclosed during the presentation at the conference [2][3]. Conference Presentation - A presentation by Silexion will occur during the conference's Innovation track on March 28th at 1:00 PM, where the company will share its strategic vision and recent preclinical findings related to SIL204 [3]. - The management team will be available for one-on-one meetings with interested investors during the conference [4].

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic di ...

Core Insights - Century Therapeutics, Inc. reported financial results and business highlights for the full year 2024, emphasizing a pipeline re-prioritization to focus on transformative candidates in high unmet need diseases [1][2] Financial Performance - Cash, cash equivalents, and marketable securities were $220.1 million as of December 31, 2024, down from $261.8 million as of December 31, 2023 [8] - Net cash used in operations was $110.1 million for the year ended December 31, 2024, compared to $88.3 million for the same period in 2023 [8] - Collaboration revenue was $6.6 million, an increase from $2.2 million in 2023 [8] - Research and Development (R&D) expenses rose to $107.2 million from $92.7 million in 2023, primarily due to increased research and laboratory costs [8] - General and Administrative (G&A) expenses decreased to $33.2 million from $34.7 million in 2023 [8] - The net loss for 2024 was $126.6 million, compared to a net loss of $136.7 million in 2023 [8] Clinical Pipeline Developments - The company has decided to discontinue the Phase 1 ELiPSE-1 trial early, focusing instead on CNTY-101, which is positioned to impact B-cell-mediated autoimmune diseases [2][6] - The CALiPSO-1 Phase 1 trial is set to expand in the U.S. and Europe, with the first patient enrolled and scheduled for dosing in March 2025 [6] - The CARAMEL Phase 1 investigator-initiated trial is expected to commence in mid-2025, focusing on CNTY-101 for B-cell mediated autoimmune diseases [6] Strategic Focus - The company is prioritizing four transformative programs, including CNTY-308, which targets B-cell mediated autoimmune diseases and malignancies [5][9] - CNTY-308 is engineered with Allo-Evasion™ 5.0 technology, aiming for comparable or better performance than approved autologous CAR-T therapies [7][9] - The company aims to launch allogeneic cell therapies at antibody-like scale and cost, expanding access to cell therapies [7][9]

Absci (ABSI) Q4 2024 Earnings Call March 18, 2025 04:30 PM ET Company Participants Alexander Khan - VP of Finance & Head of Investor RelationsSean McClain - Founder, CEO & DirectorZach Jonasson - Chief Financial Officer & Chief Business OfficerChristian Stegmann - Senior Vice President of Drug CreationArseniy Shabashvili - Vice PresidentJacqueline Kisa - Equity Research AssociateDebanjana Chatterjee - Director Conference Call Participants None - AnalystVikram Purohit - AnalystGil Blum - Senior AnalystRamaka ...